AbbVie is walking into a brand new future after it finally closed its $63 billion megamerger with Allergan earlier this month. But one thing will stay the same: Longtime CEO Richard Gonzalez will stay on board to helm the new company, and if 2019 was any indication, he will likely remain among biopharma's highest paid leaders.
Irish drugmaker Allergan scored a major coup in 2019, courtesy of a $63 billion buyout offer from AbbVie. In return, Allergan will be bringing over longtime blockbuster Botox.
AbbVie hit $33.27 billion in net revenue in 2019 on the back of mostly stable sales for Humira and boosts from blood cancer meds Imbruvica and Venclexta.
The top players in pharma know how to adapt. After M&A, selloffs, cost cuts and therapeutic rejigs, the companies on this list may largely wear the same names, but none look exactly as they did for last year's edition.
